Ionis Could Be A Factor In MASH With Positive Phase II Data

Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: Clinical trial
Ionis's Phase II data may put its MASH candidate in the thick of the R&D race • Source: Shutterstock

As the industry awaits the potential first approval of a metabolic-associated steatohepatitis (MASH) drug on 14 March, Ionis Pharmaceuticals, Inc. may have worked its way into the race to follow Madrigal Pharmaceuticals, Inc.’s THRβ agonist resmetirom into the market, unveiling top-line Phase II data on 13 March for its antisense DGAT2 inhibitor ION224 that met statistical significance for biopsy-demonstrated improvement in disease score along with a secondary endpoint of MASH resolution.

Key Takeaways
  • Ionis hits primary and secondary endpoints in a Phase II trial of its antisense candidate for MASH.

In the 51-week study, two doses of ION224 – 120mg and 90 mg, each dosed subcutaneously once a month –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Prilenia, Ferrer Map Out Plans For Pridopidine In Huntington’s

 

The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.

AC Immune Cuts Workforce As Key Parkinson’s Readout Nears

 

The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

More from R&D

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By 

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By 

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.